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Background: Hydrocephalus is an under-recognized presentation of progressive supranuclear palsy (PSP) and dementia
with Lewy bodies (DLB).
Methods: We describe four normal pressure hydrocephalus (NPH)-like presentations of pathology-proven PSP (n = 3)
and DLB (n = 1) and review the literature on the hydrocephalic presentation of these atypical parkinsonisms.
Results: Despite the presence of ventriculomegaly disproportionate to the extent of parenchymal atrophy, all patients
demonstrated early postural impairment and/or oculomotor abnormalities that encouraged a diagnostic revision.
Hallucinations were the only early atypical manifestation of the hydrocephalic DLB presentation.
Conclusions: Early postural impairment, falls, oculomotor impairment, and/or hallucinations are inconsistent with the
diagnosis of NPH and suggest PSP or DLB as the underlying NPH mimic. We postulate that previously reported cases of
“dual” pathology (e.g., NPH and PSP) actually represent the hydrocephalic presentation of selected neurodegenerative
disorders.
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Hydrocephalus as an imaging finding is commonly inter-
preted as potentially representing normal pressure
hydrocephalus (NPH) largely because of the favorable
therapeutic implications [1]. However, NPH is a rela-
tively rare disorder, recently calculated to be 1.19/
100,000/year, and reduced further to 0.36/100,000/year
when defined as sustained improvement at 3 years after
ventriculoperitoneal shunt (VPS) placement [1]. Between
1995 and 2003, from 411 patients referred as NPH to
the Mayo Clinic, only 41 were tentatively endorsed as
such and barely 14 experienced gait improvement after a
trial of cerebrospinal fluid removal, the sine qua non for
the diagnosis. Of the 12 patients who underwent VPS
placement, definite gait improvement was present in
only 6 by one year and just 4 after 3 years, one third of
the original VPS-treated cohort. Remarkably, pathology
available in 5 patients in the VPS-treated cohort revealed
the presence of neurodegenerative disorders, progressive* Correspondence: alberto.espay@uc.edu
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unless otherwise stated.supranuclear palsy (PSP) and dementia with Lewy bodies
(DLB), each accounting for a case.
Because of the large volume of NPH referrals to tertiary
care centers, predicting a sustained response to VPS place-
ment is paramount to justifying this invasive procedure.
We examined four patients referred to us for suspected
NPH but whose pathology demonstrated PSP and DLB.
The preliminary diagnosis of NPH in these patients was
based on the interpretation of imaging features, namely the
presence of hydrocephalus judged disproportionate to the
extent of surrounding parenchymal atrophy. While a care-
ful neurological examination suggested further NPH work
up was unwarranted in three patients, cerebrospinal fluid
diversion in one (case 4) supported this diagnosis by yield-
ing subjective benefits in gait and urinary function. In
addition to early impairment postural reflexes, other clinical
red flags against NPH emerged between 12 and 24 months.
We suggest that PSP and DLB, as previously reported for
Alzheimer disease (AD), is capable of generating a neuro-
imaging profile suggestive of communicating hydroceph-
alus, with ventriculomegaly disproportionate to the extent
of parenchymal atrophy, prompting a diagnostic consider-
ation for NPH and potentially misdirecting treatment to-
ward cerebrospinal fluid diversion.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Case reports
Four consecutive patients referred to our center for sus-
pected NPH for whom brain autopsy was obtained were
identified in our center from the years 2007–2012. After
evaluation in our center, VPS placement was discouraged
for the first three patients but pursued in the fourth to
no avail. Written informed consent was obtained from
all patients for the publication of patient-related data
and videotapes.Results
Case 1
This 68-year-old woman developed balance impairment
followed by falls, mostly forward, urinary incontinence,
and intermittently slurred speech over a 2-year period.
Head CT demonstrated mild to moderate hydrocephalusFigure 1 Neuroimaging of the NPH suspected cases. Head CT (A) and FL
moderate ventriculomegaly (upper row), with relatively mild or absent (Case 3
(middle row). Some degree of midbrain atrophy is appreciable in all cases, inc
clinical picture that suggested a rapidly progressive form of PSP. Leukoenceph
lobe was due to remote stroke in Case 4.(Figure 1A), prompting referral for VPS placement. On
neurological examination, she exhibited a tremorless par-
kinsonian phenotype with cognitive impairment (MMSE =
19/30) associated with echolalia, growling dysarthria, and
hypomimia, prompting a revised clinical diagnosis of PSP.
By three years from symptom onset, she developed square-
wave jerks, slow saccades, and supranuclear vertical gaze
palsy (Additional file 1: Video S1). Donepezil, rivastigmine,
and memantine trials provided no benefit. She died after
six years from symptom onset. Neuropathological stud-
ies confirmed the diagnosis of PSP with concurrent AD
neuropathologic changes (Braak stage II; CERAD score
A) and mild associated arteriolosclerosis and athero-
sclerosis (Figure 2A-D).
Case 2
This 79-year-old man developed difficulty with “complex”
leg movements, such as those required when walking acrossAIR sequences of brain MRI (B-D) for cases 1–4 (A-D) showed mild to
) associated parenchymal atrophy as judged by the apical axial cuts
luding the one ultimately diagnosed as DLB on pathology (C) despite a
alomalacia in the right cerebellar hemisphere and left parasagittal frontal
Figure 2 Neuropathology images of selected cases. A. (Case 1) Coronal section demonstrating enlargement of the anterior horns of the
lateral ventricles. B. (Case 1) Tufted astrocytes and tau positive neurons in the caudate nucleus (tau stain (AT8), magnification 200×). C. (Case 1)
Coiled bodies in the parietal white matter (tau stain (AT8), magnification 400×). D. (Case 1) Tufted astrocytes and tau positive neurons in the
parietal cortex (tau stain (AT8), magnification 200×). E. (Case 3) Lewy bodies in the substantia nigra (H&E, magnification 400×). F. (Case 3)
Substantia nigra, Lewy bodies and Lewy neuritis (alpha-synuclein, magnification 200×).
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within one year was interpreted as mild hydrocephalus
(Figure 1B), prompting a referral for was consideration of
VPS placement. His examination showed parkinsonism
with marked gait and postural impairment, upgaze restric-
tion, and stimulus-sensitive axial myoclonus (Additional
file 2: Video S2), as well as mild dysexecutive impairment
(MMSE = 28/30; Frontal Assessment Battery = 14/18;
Montreal Cognitive Assessment = 25/30). His revised
clinical diagnosis was PSP and VPS placement was
discouraged. Death occurred 10 years after symptom
onset. Post-mortem studies confirmed the diagnosis of
PSP with associated low-grade AD neuropathology (Braak
stage II; CERAD score A) and brainstem Lewy bodies.
Case 3
This 73-year-old man initially exhibited falls, visual hal-
lucinations, irritability and combative behavior. Withintwo months he was unable to ambulate independently
and had noticeable memory loss. Brain MRI taken at
3 months from symptom onset demonstrated moderate
ventriculomegaly without overt atrophy in the apical
cuts, suggesting the diagnosis of NPH (Figure 1C). How-
ever, in short sequence he developed dysarthria evolving
to anarthria, severe dysphagia, and needed assistance for
all activities of daily living. At 5 months, his examination
showed retrocollis with axial-predominant rigidity and
ophthalmoplegia, taking place at one of his “bad spells”
(Additional file 3: Video S3). Cognitive assessment was
impossible given marked dysarthria. Rivastigmine pro-
vided no benefits but donepezil eliminated his visual hal-
lucinations. A rapidly progressive form of PSP was
suspected and shunting was discouraged. Despite the
early rapid progression, death from aspiration pneumonia
occurred six years after symptom onset. Post-mortem
neuropathology unexpectedly revealed DLB (neocortical
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F) with mild to moderate arteriolosclerosis and mild AD
neuropathology (Braak stage II; CERAD score A).
Case 4
This 72-year-old man with progressive gait and balance
impairment underwent a brain MRI, which upon pres-
ence of hydrocephalus, hyperdynamic fluid signal in the
third ventricle, and entrapped sulci in several cortical
areas (Figure 1D) prompted a referral to our center. Ini-
tial examination 18 months after symptom onset demon-
strated mild non-fluent aphasia, visuospatial dysfunction,
and delayed recall (MMSE = 24; Montreal Cognitive As-
sessment = 13/30] in the setting of wide based, unsteady
gait. Mild impairment of upgaze with absent vertical opto-
kinetic responses was present at the initial examination
(Additional file 4: Video S4). External lumbar drainage
provided benefits in gait and urinary function. VPS place-
ment, however, was followed by improvements in gait and
urinary function for about 6 months, followed by deterior-
ation of his overall parkinsonism and cognitive function.
He developed frontal release signs and disinhibition, with
worsening of dysexecutive dementia, mild facial dystonia,
greater oculomotor dysfunction (impairment of upgaze,
slowed downgaze, square-wave jerks), and marked pos-
tural impairment with backward falls. He died from aspir-
ation pneumonia six years from onset of symptoms.
Suspected PSP was confirmed on postmortem studies,
which also revealed unusually marked and widespread oc-
cipital cortical involvement.
Discussion
There are two major shortcomings in the appraisal of
NPH as an entity, namely the absence of clinical and
pathological biomarkers and the reliance on short-term
response to drainage for its definition [2], which often
does not “hold water” in the long term [1]. Indeed, the
longer the follow up, the lower the frequency of re-
sponse, and the higher the diagnostic revision rate [1].
Important lessons derived from the suspected NPH pa-
tients presented here were that cognitive impairment
predated or occurred concurrently with gait dysfunction,
and impairment of postural reflexes was universal. This
is in keeping with the observation that postural instabil-
ity at the initial evaluation of a suspected NPH patient
predicts the absence of sustained improvement at 3 years
from VPS placement [1].
Besides early impairment of postural reflexes, our pa-
tients had early cognitive impairment, either predating or
occurring concurrently with gait impairment. Cognitive
impairment is a regrettable component of the “classic”
NPH triad. Of the 8 cognitively impaired VPS-treated pa-
tients in the Mayo Clinic series, only 1 continued to bene-
fit at 3 years [1]. This implies that by the time a patientwith hydrocephalus develops cognitive impairment, the
odds of shunt responsiveness are substantially low, and
diagnostic considerations other than NPH are warranted.
Patients may have AD if cognitive impairment predomi-
nates [3] and PSP or DLB if parkinsonism is an important
clinical manifestation. In the former situation, AD bio-
markers may be particularly helpful in discriminating AD
from true NPH. In a sample of 37 prospectively followed
VPS-treated “NPH” patients, poor sustained response was
predicted by the presence of amyloid β plaques, neuritic
plaques, and/or neurofibrillary tangles observed in cortical
biopsies taken at the time of shunt insertion [3]. Cortical
biopsies identified amyloid-β aggregates in over half of
presumed NPH patients who had initial response to VPS
but eventual progression of dementia [4]. Similarly, 8 out
of 9 patients with clinically diagnosed NPH that came to
autopsy at the Sun Health Research Institute within a 12-
year period, demonstrated AD pathology (one also with
DLB) and the other met pathologic criteria for PSP [5].
A major pitfall of the interpretation of these data is to as-
sume that these patients had “co-occurrence” of AD and
NPH [5,6], rather than the hydrocephalic presentation of a
single, neurodegenerative disorder. This potential misinter-
pretation is giving rise to reports of NPH patients “evolv-
ing” to AD [7], without considering the possibility that
NPH may have been an early clinical misdiagnosis. Al-
though the postulation of an “AD-NPH syndrome” [8,9]
has already led to a negative clinical trial [10], clinicians
continue to offer VPS to patients with hydrocephalus in the
setting of dementia, because it is part of the “classic triad”
(conversely, some neurosurgeons may be reluctant to shunt
if dementia is not present in patients whose hydrocephalus
may “only” be associated with gait impairment).
PSP appears to be the most common etiology of sus-
pected NPH with a parkinsonian phenotype (Table 1). It
was present in 3 of 4 such cases from the Queen Square
Brain Bank, none of whom had, at presentation, any
oculomotor dysfunction [11]. However, postural instabil-
ity and mild dysexecutive impairment were present in
all. VPS placement in three resulted in short-term bene-
fits but subsequent deterioration ensued within one year.
The early Toronto experience showed that 3 of 5 NPH
patients with hydrocephalus and early response to VPS
evolved into a parkinsonian phenotype confirmed to
represent PSP in two (one with pathology confirmation)
and DLB in another [12].
Our cases and the review of the literature highlight sev-
eral key clinically relevant messages: 1) early cognitive im-
pairment is the most important “cognitive red flag” of the
NPH triad and predicts an alternative diagnosis; 2) early
impairment of postural reflexes, with or without falls, is
the most common “motor red flag” of the NPH triad, and
should suggest PSP or DLB; 3) visual hallucinations are a
strong clinical biomarker of synucleinopathies [13] and






Initial clinical features Late clinical features Response to VPS Pathology
1 [1] 82, F* 1.1 years GD, CI, UI, postural
instability
N/A Transient improvement in
GD/UI; worse at 3 years
PSP
2 [5] 77, M♣ N/A GD, CI, UI N/A VPS placed, outcome data not
available
PSP
3 [11] 78, F 2 years GD, CI, UI, falls, generalized
bradykinesia, dysarthria
Restriction of vertical eye movements,
hypophonia, frontal release signs
Not placed PSP
4 [11] 68, M 4 months GD, CI, UI, gait ignition
failure, falls, hypomimia,
micrographia
Restriction of vertical gaze, slow




5 [11] 66, F 2 years GD, CI, falls, micrographia Restriction of vertical gaze, slow






6 [12] 69, M N/A GD, CI, UI VSGP, akinesia, rigidity 6-month “marked”
improvement in GD, CI, and
UI
PSP
7 [1] 66, F♦ 3.1 years GD, CI, UI, postural
instability
“Clinical diagnosis of DLB” Some improvement in GD at
3–6 months; no improvement
at 3 years
DLB
8 [5] 80, M♠ N/A GD, CI N/A VPS placed, outcome data not
available
DLB
9 [7] 87, F 2 years GD, CI, UI Postural instability, falls, rare visual
hallucinations
Initial marked improvement in
GD/CI – No follow-up data.
DLB
GD: gait disturbance; CI: cognitive impairment; UI: urinary incontinence; VSGP: vertical supranuclear gaze palsy. *: VPS placed at 82 (no age at presentation given);
♣: Death at 77 (no age at presentation given); ♦: VPS placed at 66 (no age at presentation given); ♠: Death at 80 (no age at presentation given).
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diagnostic yield toward DLB; and 4) a “honeymoon”
period may occur after shunting in patients with PSP but
further progression would be expected thereafter. To the
extent that transient symptomatic relief in the setting of a
neurodegenerative disorder may be preferable to no relief
at all, the approach to a hydrocephalic patient with “red
flags” may still include fluid diversion, but patients and
families need to be counseled about the anticipated short-
term gains.
In sum, hydrocephalus in the setting of postural im-
pairment and/or oculomotor abnormalities most prob-
ably represents PSP or DLB. Hallucinations may be the
only early manifestation of the hydrocephalic presenta-
tion of DLB. An initial promising response to VPS place-
ment does not exclude the possibility of an underlying
neurodegenerative disease. Furthermore, a fully formed
“classic” triad of gait impairment, urinary incontinence,
and cognitive impairment appears to be more common
in conditions other than NPH. The accumulating evi-
dence suggests that early postural impairment, falls,
oculomotor impairment, or hallucinations are inconsist-
ent with the diagnosis of NPH regardless of ventricular
size. Recognition of the hydrocephalic presentation of
PSP and DLB can avoid unnecessary and potentially
harmful shunting procedures.Additional files
Additional file 1: Video S1. Patient 1 shows growling dysarthria,
restriction of upgaze with supranuclear vertical gaze palsy, appendicular
dystonia with dysmetria, wide-based, short-stride gait with erect posture,
mild retrocollis, and impaired postural reflexes.
Additional file 2: Video S2. Patient 2 demonstrates upgaze restriction
with nystagmus but no square-wave jerks or slow saccades. There was marked
gait impairment with wide base support and retropulsion on pull test.
Additional file 3: Video S3. Patient 3 shows marked retrocollis, severe
dysarthria and ophthalmoplegia. Patient is videotaped over the course of a
“bad spell”, in hindsight interpreted as part of his DLB-associated cognitive
fluctuations.
Additional file 4: Video S4. Patient 4 shows a wide based, unsteady
gait. Disappearance of corrective saccades to the optokinetic strip was
the early clue as to his subtle saccadic impairment, and predated a later
development of supranuclear vertical gaze palsy.
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